AEON AEON Biopharma, Inc.

AEON financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1837607 Exchange: NYSE SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Aug 12, 2026 Data checked: Oct 21, 2026
Showing 3 of 4 annual and 0 of 21 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
<br>Emerging growth company
Entity Type
Operating
Public Float
$8.70M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
(949) 354-6499
EIN
853940478
Headquarters
ALISO VIEJO, CA, 92656
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: Priveterra Acquisition Corp. (2020–2023)

▼ Key Metrics (TTM)

As of Jun 30, 2026
Financials
Revenue
-
Net Income
$-54.62M
Total Assets
$5.91M
Total Equity
$-15.36M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
355.6%
Return on Assets
-924.2%
Current Ratio
0.54x

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

Fiscal 2025 results for AEON Biopharma, Inc. included net loss of $39.22M. Diluted earnings per share were -$3.95, translating the period’s attributable earnings into the amount reported for each diluted share. The per-share result recorded a 105.4% decrease from fiscal 2024 diluted EPS of $72.93. Diluted shares averaged 9.92M; this is the reported share base over which the company’s diluted per-share earnings were spread. At period end, total assets were $5.56M, framing the scale of the company’s operating and financing commitments.

Profitability

The reported operating result was an operating loss of $12.80M, reflecting costs that exceeded gross profit. The company ended the period with a net loss of $39.22M, extending the operating result through all remaining items. Negative EBITDA totaled $12.72M, confirming that the earnings deficit remained before depreciation and amortization. The pretax result was a loss of $39.22M, establishing the deficit before tax effects. The company recognized $0.00 of income tax for the period, completing the transition from pretax income to net income. The loss-to-assets relationship was 705.4%, placing the bottom-line deficit against the company’s resource base. The company moved from fiscal 2024 net income of $42.01M to a current net loss of $39.22M.

Liquidity and Capital Structure

At period end, the $5.56M asset base was financed through $60.59M of liabilities and -$55.03M of equity. Equity was negative at -$55.03M, meaning liabilities exceeded the residual book value available to shareholders and weakening balance-sheet resilience. At period end, current assets of $3.40M compared with current liabilities of $6.90M, defining the company’s short-term resource position. Current assets covered only 0.49x of current liabilities, so current liabilities exceeded current assets at period end. Cash and equivalents totaled $3.01M, identifying the most liquid reported component available within the broader current-asset balance. Cash and equivalents represented 43.6% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Equity equaled -989.7% of assets, showing the shareholder-capital layer within the company’s balance sheet. The cash-to-assets relationship was 54.1%, comparing reported cash and equivalents with the full positive asset balance. The asset base changed 77.0% from $3.14M in fiscal 2024, leaving current total assets higher year over year.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $17.31M, showing that operations absorbed cash during the period. The company spent $4.00K on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. Negative free cash flow was $17.31M, leaving a cash deficit after capital spending and reducing financial flexibility. The free-cash-flow deficit equaled 311.4% of total assets, placing the cash shortfall against the company’s resource base. Compared with a $20.29M operating cash outflow in fiscal 2024, the current outflow improved to $17.31M.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for AEON Biopharma, Inc.
Metric FY2025 📄 FY2024 📄 FY2022 📄
Income Statement
REVENUE
OPERATING EXPENSES
R&D Expense $4.09M $14.18M $34.75M
SG&A Expense $12.21M $13.64M $13.68M
Operating Income $-12.80M $72.99M $-48.43M
NON-OPERATING INCOME / EXPENSE
Interest Income - - $3.71M
Other Income/Expense $290.00K $95.00K $289.00K
Pretax Income $-39.22M $42.01M $-52.56M
Income Tax $0 $0 $0
Net Income $-39.22M $42.01M $-52.56M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-3.95 $72.93 $-27.36
Diluted Shares 9.92M 575.95K 1.93M
EBITDA $-12.73M $73.08M $-48.36M
Depreciation & Amortization $78.00K $97.00K $68.00K
Balance Sheet
ASSETS
Cash & Equivalents $3.01M $13.00K $9.75M
Other Current Assets $392.00K $1.58M $92.00K
Current Assets $3.40M $1.59M $9.84M
PP&E (Net) $162.00K $235.00K $431.00K
Other Noncurrent Assets $948.00K $29.00K $34.00K
Noncurrent Assets $2.16M $1.55M $940.00K
Total Assets $5.56M $3.14M $10.78M
LIABILITIES
Accounts Payable $942.00K $5.91M $7.81M
Other Current Liabilities $1.66M $3.60M $740.00K
Current Liabilities $6.90M $14.15M $82.57M
Noncurrent Liabilities $53.69M $17.56M $60.67M
Total Liabilities $60.59M $31.71M $143.24M
EQUITY
Common Stock $9.00K $4.00K $14.00K
Additional Paid-in Capital $415.78M $403.02M $32.00K
Retained Earnings $-470.82M $-431.60M $-474.84M
Total Equity $-55.03M $-28.57M $-270.41M
Temporary Equity - - $137.95M
Total Liabilities & Equity $5.56M $3.14M $10.78M
SUPPLEMENTAL
Shares Outstanding 12.11M 555.51K 138.83M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-17.31M $-20.29M $-35.58M
Capital Expenditures $4.00K - $306.00K
Cash from Investing $-4.00K $0 $-306.00K
Cash from Financing $20.31M $15.15M $40.51M
Free Cash Flow $-17.31M - $-35.89M
Beginning Cash (CFS) $13.00K $5.16M $5.13M
Net Change in Cash $2.99M $-5.15M $4.62M
Effect of FX on Cash - - -
Calculated Ending Cash $3.01M $13.00K $9.75M
Cash per BS $3.01M $13.00K $9.75M
Cash scope difference (CFS − BS) - - -
Cash per CFS $3.01M $13.00K $9.75M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

Is AEON Biopharma, Inc. profitable?

No. AEON Biopharma, Inc. reported $-54.62M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.